FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Herbert Tilg

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Mouse

Anatomy

Cells, Cultured

Co-author Network

Publications

TOP 3
Herbert Tilg; Alexander R Moschen
Gut microbiota: Malnutrition and microbiota-a new relationship?
Michael Trauner; Peter Fickert; Herbert Tilg
Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison.
Richard Skoien; Herbert Tilg; Martin Weltman; Ulrich Baumann; Prithi S Bhathal; Rachel M Brown; Elizabeth M Brunt; Richard T Couper; John B Dixon; Looi C Ee; Julie R Jonsson; Nicholas D Manton; Alexander R Moschen; Brent A Neuschwander-Tetri; Paul E O'Brien; Elizabeth E Powell; Michelle M Richardson; Andrew D Clouston
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Herbert Tilg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Herbert Tilg; Alexander R Moschen
Gut microbiota: Malnutrition and microbiota-a new relationship?
Nature reviews. Gastroenterology & hepatology 2013;10(5):261-2.
2013: Michael Trauner; Peter Fickert; Herbert Tilg
Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison.
Gastroenterology 2013;144(4):844-6.
2013: Richard Skoien; Herbert Tilg; Martin Weltman; Ulrich Baumann; Prithi S Bhathal; Rachel M Brown; Elizabeth M Brunt; Richard T Couper; John B Dixon; Looi C Ee; Julie R Jonsson; Nicholas D Manton; Alexander R Moschen; Brent A Neuschwander-Tetri; Paul E O'Brien; Elizabeth E Powell; Michelle M Richardson; Andrew D Clouston
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.
Liver international : official journal of the International Association for the Study of the Liver 2013;33(4):624-32.
2013: Verena Wieser; Alexander R Moschen; Herbert Tilg
Inflammation, cytokines and insulin resistance: a clinical perspective.
Archivum immunologiae et therapiae experimentalis 2013;61(2):119-25.
2013: Stefan Kiechl; Trayana Kireva; Michael Knoflach; Florian Kronenberg; Julia Luther; Agnes Mayr; James B Meigs; Dirk Mielenz; Alexander R Moschen; Giovanna Muscogiuri; Friedrich Oberhollenzer; Michael Orthofer; Josef M Penninger; Ulrike Billmeier; Enzo Bonora; Aline Bozec; Georg Egger; Andrea Giaccari; Gian Pio Sorice; Monika Summerer; Herbert Tilg; Johann Willeit; Peter Willeit; Stefan Wirtz; Jürgen Wittmann; Georg Schett
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.
Nature medicine 2013;19(3):358-63.
2013: Gert Van Assche; Laurent Beaugerie; Bernd Bokemeyer; Silvio Danese; Axel Dignass; Paolo Gionchetti; Fernando Gomollón; Winfried Häuser; Klaus Herrlinger; Gabriele Moser; Bas Oldenburg; Julian Panes; Francisco Portela; Gerhard Rogler; Jürgen Stein; Herbert Tilg; Simon Travis; James O Lindsay
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.
Journal of Crohn's & colitis 2013;7(1):1-33.
2012: Alexander R Moschen; Verena Wieser; Herbert Tilg
Dietary Factors: Major Regulators of the Gut's Microbiota.
Gut and liver 2012;6(4):411-6.
2012: Wilhelm Grander; Bernhard Koller; Johannes Schwaiger; Herbert Tilg; Martin W Dünser
Determinants of exercise capacity in dilated cardiomyopathy: a prospective, explorative cohort study.
Wiener klinische Wochenschrift 2012;124(19-20):685-91.
2012: Arthur Kaser; Herbert Tilg
"Metabolic aspects" in inflammatory bowel diseases.
Current drug delivery 2012;9(4):326-32.
2012: Herbert Tilg; Julian R Marchesi
Too much fat for the gut's microbiota.
Gut 2012;61(4):474-5.
2012: Verena Wieser; Alexander R Moschen; Herbert Tilg
Adipocytokines and hepatocellular carcinoma.
Digestive diseases (Basel, Switzerland) 2012;30(5):508-13.
2012: Herbert Tilg; Rick Blumberg; Stefan Enders; Arthur Kaser; Michael Manns
Innate immunity in gastrointestinal disorders: basic and therapeutic concepts.
Digestive diseases (Basel, Switzerland) 2012;30 Suppl 1():1.
2012: Alexander R Moschen; V Wieser; Herbert Tilg
Adiponectin: key player in the adipose tissue-liver crosstalk.
Current medicinal chemistry 2012;19(32):5467-73.
2011: Herbert Tilg; Alexander R Moschen
IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation.
Journal of hepatology 2011;55(5):960-2.
2011: Herbert Tilg; Alexander R Moschen; Nicole C Kaneider
Pathways of liver injury in alcoholic liver disease.
Journal of hepatology 2011;55(5):1159-61.
2011: Jochen Zwerina; Stefan Wieczorek; Christian Bach; Jan Bremer; Guido Hegasy; Maria Jatzwauk; davide martorana; Frank Moosig; Alexander Moschen; Thomas Neumann; Georg Schett; Bernd M Spriewald; Herbert Tilg; Augusto Vaglio
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study.
Rheumatology (Oxford, England) 2011;50(10):1823-7.
2011: Alexander Tschoner; Julia Engl; Susanne Kaser; Alexander Klaus; Elisabeth Laimer; Markus Laimer; Josef R Patsch; Claudia Ress; Wolfgang Sturm; Herbert Tilg; Christoph Ebenbichler
Effect of weight loss on serum pigment epithelium-derived factor levels.
European journal of clinical investigation 2011;41(9):937-42.
2011: Alexander R Moschen; Andrea Schroll; Teresa Fritz; Romana Gerner; Arthur Kaser; Herbert Tilg
A key role for Pre-B cell colony-enhancing factor in experimental hepatitis.
Hepatology (Baltimore, Md.) 2011;54(2):675-86.
2011: C Ress; N Sausgruber; Wilfried Schgoer; Herbert Tilg; A Tschoner; Helmut Weiss; Christoph Ebenbichler; Ivo W Graziadei; R J Konrad; Alexander R Moschen; Josef R Patsch; Susanne Kaser
The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Gut 2011;60(7):985-91.
2011: Herbert Tilg; Arthur Kaser
Gut microbiome, obesity, and metabolic dysfunction.
The Journal of clinical investigation 2011;121(6):2126-32.
2011: Herbert Tilg; Anna Mae Diehl
NAFLD and extrahepatic cancers: have a look at the colon.
Gut 2011;60(6):745-6.
2011: Alexander R Moschen; Teresa Fritz; Andrew D Clouston; Ilka Rebhan; Oliver Bauhofer; Helen D Barrie; Elizabeth E Powell; Soo-Hyun Kim; Charles A Dinarello; Ralf Bartenschlager; Julie R Jonsson; Herbert Tilg
Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis.
Hepatology (Baltimore, Md.) 2011;53(6):1819-29.
2011: Trayana Kireva; Annette Erhardt; Gisa Tiegs; Herbert Tilg; Helmut Denk; Johannes Haybaeck; Elmar Aigner; Alexander Moschen; Jörg H Distler; Georg Schett; Jochen Zwerina
Transcription factor Fra-1 induces cholangitis and liver fibrosis.
Hepatology (Baltimore, Md.) 2011;53(4):1259-69.
2011: Herbert Tilg; Alexander R Moschen
Relevance of TNF-α gene polymorphisms in nonalcoholic fatty liver disease.
Expert review of gastroenterology & hepatology 2011;5(2):155-8.
2011: Manfred Nairz; Andrea Schroll; Alexander R Moschen; Thomas Sonnweber; Milan Theurl; Igor Theurl; Nicole Taub; Christina Jamnig; Daniela Neurauter; Lukas A Huber; Herbert Tilg; Patrizia L Moser; Günter Weiss
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways.
Immunity 2011;34(1):61-74.
2011: Werner Vogetseder; Herbert Tilg
Abdominal pain beyond IBS. Hereditary angioedema (HAE type III).
Gastroenterology 2011;140(1):34, 371.
2010: Herbert Tilg; Alexander R Moschen
Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target.
Gastroenterology 2010;139(6):1823-6.
2010: Herbert Tilg; Arthur Kaser
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.
Current opinion in investigational drugs (London, England : 2000) 2010;11(11):1295-304.
2010: Herbert Tilg; Alexander R Moschen
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.
Hepatology (Baltimore, Md.) 2010;52(5):1836-46.
2010: Teresa Fritz; Lukas Niederreiter; Herbert Tilg; Richard S Blumberg; Arthur Kaser
Controversy over NOD2, inflammation, and defensins.
Inflammatory bowel diseases 2010;16(11):1996-8.
2010: Wilhelm Grander; Martin Dünser; Björn Stollenwerk; Uwe Siebert; Clemens Dengg; Bernhard Koller; Patricia Eller; Herbert Tilg
C-reactive protein levels and post-ICU mortality in nonsurgical intensive care patients.
Chest 2010;138(4):856-62.
2010: Alexander R Moschen; Clemens Molnar; Sabine Geiger; Ivo W Graziadei; Christoph Ebenbichler; Helmut Weiss; Susanne Kaser; Arthur Kaser; Herbert Tilg
Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression.
Gut 2010;59(9):1259-64.
2010: Gottfried Novacek; Ansgar Weltermann; Anna Sobala; Herbert Tilg; Wolfgang Petritsch; Walter Reinisch; Andreas Mayer; Thomas Haas; Arthur Kaser; Thomas Feichtenschlager; Harry Fuchssteiner; Peter Knoflach; Harald Vogelsang; Wolfgang Miehsler; Reingard Platzer; Wolfgang Tillinger; Bernhard Jaritz; Alfons Schmid; Benedikt Blaha; Clemens Dejaco; Sabine Eichinger
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
Gastroenterology 2010;139(3):779-87, 787.e1.
2010: Herbert Tilg
Obesity, metabolic syndrome, and microbiota: multiple interactions.
Journal of clinical gastroenterology 2010;44 Suppl 1():S16-8.
2010: Elmar Aigner; Michael Strasser; Heike Haufe; Thomas Sonnweber; Florian Hohla; Andreas Stadlmayr; Marc Solioz; Herbert Tilg; Wolfgang Patsch; Guenter Weiss; Felix Stickel; Christian Datz
A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
The American journal of gastroenterology 2010;105(9):1978-85.
2010: Alexander R Moschen; Sabine Geiger; Romana Gerner; Herbert Tilg
Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease.
Mutation research 2010;690(1-2):95-101.
2010: Herbert Tilg; Alexander R Moschen
Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.
Current opinion in clinical nutrition and metabolic care 2010;13(4):391-6.
2010: Susanne Kaser; Christoph Ebenbichler; Herbert Tilg
Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.
International journal of clinical practice 2010;64(7):968-83.
2010: Herbert Tilg; Alexander R Moschen
Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
Minerva gastroenterologica e dietologica 2010;56(2):159-67.
2010: Herbert Tilg
Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
Current pharmaceutical design 2010;16(17):1893-5.
2010: Alexander R Moschen; Romana R Gerner; Herbert Tilg
Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders.
Current pharmaceutical design 2010;16(17):1913-20.
2010: Claudia Ress; Alexander Tschoner; Christian Ciardi; Markus W Laimer; Julia W Engl; Wolfgang Sturm; Helmut Weiss; Herbert Tilg; Christoph Ebenbichler; Josef R Patsch; Susanne Kaser
Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels.
European cytokine network 2010;21(1):65-70.
2010: C Ress; A Tschoner; Julia Engl; Alexander Klaus; Herbert Tilg; Christoph Ebenbichler; Josef R Patsch; Susanne Kaser
Effect of bariatric surgery on circulating chemerin levels.
European journal of clinical investigation 2010;40(3):277-80.
2010: Herbert Tilg
The role of cytokines in non-alcoholic fatty liver disease.
Digestive diseases (Basel, Switzerland) 2010;28(1):179-85.
2009: Herbert Tilg; Arthur Kaser
Adiponectin and JNK: metabolic/inflammatory pathways affecting gastrointestinal carcinogenesis.
Gut 2009;58(12):1576-7.
2009: Alexander R Moschen; Clemens Molnar; Anna Maria Wolf; Helmut Weiss; Ivo W Graziadei; Susanne Kaser; Christoph Ebenbichler; Sylvia Stadlmann; Patrizia L Moser; Herbert Tilg
Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression.
Journal of hepatology 2009;51(4):765-77.
2009: Wolfgang Sturm; Anton Sandhofer; Julia Engl; Markus Laimer; Clemens Molnar; Susanne Kaser; Helmut Weiss; Herbert Tilg; Christoph Ebenbichler; Josef R Patsch
Influence of visceral obesity and liver fat on vascular structure and function in obese subjects.
Obesity (Silver Spring, Md.) 2009;17(9):1783-8.
2009: Herbert Tilg; Alexander R Moschen; Arthur Kaser
Obesity and the microbiota.
Gastroenterology 2009;136(5):1476-83.
2009: Herbert Tilg; Alexander R Moschen; Arthur Kaser
Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?
European cytokine network 2009;20(1):1-6.
2009: Arthur Kaser; Herbert Tilg
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008.
Expert opinion on therapeutic targets 2009;13(2):259-63.
2008: Herbert Tilg; Alexander R Moschen
Insulin resistance, inflammation, and non-alcoholic fatty liver disease.
Trends in endocrinology and metabolism: TEM 2008;19(10):371-9.
2008: Herbert Tilg
Short bowel syndrome: searching for the proper diet.
European journal of gastroenterology & hepatology 2008;20(11):1061-3.
2008: Arthur Kaser; Ann-Hwee Lee; Andre Franke; Jonathan N Glickman; Sebastian Zeissig; Herbert Tilg; Edward E S Nieuwenhuis; Darren E Higgins; Stefan Schreiber; Laurie H Glimcher; Richard S Blumberg
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease.
Cell 2008;134(5):743-56.
2008: Alexander R Moschen; Herbert Tilg
Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease.
Current opinion in clinical nutrition and metabolic care 2008;11(5):620-5.
2008: Julia Engl; Christian Ciardi; Tobias Tatarczyk; Susanne Kaser; Markus Laimer; Elisabeth Laimer; Helmut Weiss; Franz Aigner; Clemens Molnar; Herbert Tilg; Josef R Patsch; Christoph Ebenbichler
A-FABP--a biomarker associated with the metabolic syndrome and/or an indicator of weight change?
Obesity (Silver Spring, Md.) 2008;16(8):1838-42.
2008: Hans P Groechenig; Werner Vogetseder; Herbert Tilg
Chest pain after gastrointestinal endoscopic examination.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(7):A32.
2008: Arthur Kaser; Herbert Tilg
Novel therapeutic targets in the treatment of IBD.
Expert opinion on therapeutic targets 2008;12(5):553-63.
2008: Herbert Tilg; Alexander R Moschen; Arthur Kaser; A Pines; I Dotan
Gut, inflammation and osteoporosis: basic and clinical concepts.
Gut 2008;57(5):684-94.
2008: Julia Engl; Wolfgang Sturm; Anton Sandhofer; Susanne Kaser; A Tschoner; Tobias Tatarczyk; Helmut Weiss; Herbert Tilg; Josef R Patsch; Christoph Ebenbichler
Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms.
European journal of clinical investigation 2008;38(4):238-44.
2008: Herbert Tilg; Alexander R Moschen
Inflammatory mechanisms in the regulation of insulin resistance.
Molecular medicine (Cambridge, Mass.) 2008;14(3-4):222-31.
2008: Herbert Tilg; Alexander R Moschen
Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.
Clinical science (London, England : 1979) 2008;114(4):275-88.
2008: Alexander R Moschen; Sabine Geiger; Ingomar Krehan; Arthur Kaser; Herbert Tilg
Interferon-alpha controls IL-17 expression in vitro and in vivo.
Immunobiology 2008;213(9-10):779-87.
2008: Othmar Ludwiczek; Edouard Vannier; Alexander Moschen; Adriana Salazar-Montes; Ingo Borggraefe; Cem Gabay; Barbara Enrich; Arthur Kaser; Britta Siegmund; Charles Dinarello; Herbert Tilg
Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease.
Scandinavian journal of gastroenterology 2008;43(11):1360-5.
2007: Holger Rumpold; Christina Salvador; Anna Maria Wolf; Herbert Tilg; Guenther Gastl; Dominik Wolf
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
Biochemical and biophysical research communications 2007;361(2):549-54.
2007: Gudrun Ratzinger; N Sepp; W Vogetseder; Herbert Tilg
Cheilitis granulomatosa and Melkersson-Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients.
Journal of the European Academy of Dermatology and Venereology : JEADV 2007;21(8):1065-70.
2007: Herbert Tilg; Alexander R Moschen; Arthur Kaser
Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.
Expert opinion on biological therapy 2007;7(7):1051-9.
2007: Michelle M Richardson; Julie R Jonsson; Elizabeth E Powell; Elizabeth M Brunt; Brent A Neuschwander-Tetri; Prithi S Bhathal; John B Dixon; Martin Weltman; Herbert Tilg; Alexander R Moschen; David M Purdie; Anthony J Demetris; Andrew D Clouston
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
Gastroenterology 2007;133(1):80-90.
2007: Herbert Tilg
Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria.
Expert opinion on therapeutic targets 2007;11(6):853-6.
2007: Julia Engl; Thomas Bobbert; Christian Ciardi; Markus Laimer; Tobias Tatarczyk; Susanne Kaser; Helmut Weiss; Clemens Molnar; Herbert Tilg; Josef R Patsch; Joachim Spranger; Christoph Ebenbichler
Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters.
Obesity (Silver Spring, Md.) 2007;15(5):1172-8.
2007: Matthias Lechner; Josef Rieder; Herbert Tilg
Helicobacter pylori infection, iNOS, and gastric cancer: the impact of another possible link.
Journal of surgical oncology 2007;95(3):271-2.
2007: Alexander R Moschen; Arthur Kaser; Barbara Enrich; Birgit A Mosheimer; Milan Theurl; Harald Niederegger; Herbert Tilg
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(3):1748-58.
2007: Herbert Tilg; Christopher P Day
Management strategies in alcoholic liver disease.
Nature clinical practice. Gastroenterology & hepatology 2007;4(1):24-34.
2006: Matthias Lechner; Berthold Moser; David Niederseer; Alban Karlseder; Bernhard Holzknecht; Matthias Fuchs; Stephan Colvin; Herbert Tilg; Josef Rieder
Gender and age specific differences in exhaled isoprene levels.
Respiratory physiology & neurobiology 2006;154(3):478-83.
2006: Herbert Tilg; Arthur Kaser; Alexander R Moschen
How to modulate inflammatory cytokines in liver diseases.
Liver international : official journal of the International Association for the Study of the Liver 2006;26(9):1029-39.
2006: Herbert Tilg; Alexander R Moschen
Adipocytokines: mediators linking adipose tissue, inflammation and immunity.
Nature reviews. Immunology 2006;6(10):772-83.
2006: Dominik Wolf; Holger Rumpold; Christian Koppelstätter; Guenther Gastl; Michael Steurer; Gert Mayer; Eberhard Gunsilius; Herbert Tilg; Anna Maria Wolf
Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients.
Cancer immunology, immunotherapy : CII 2006;55(10):1198-208.
2006: Anna Maria Wolf; Holger Rumpold; Herbert Tilg; Guenther Gastl; Eberhard Gunsilius; Dominik Wolf
The effect of zoledronic acid on the function and differentiation of myeloid cells.
Haematologica 2006;91(9):1165-71.
2006: Herbert Tilg; Gökhan S Hotamisligil
Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance.
Gastroenterology 2006;131(3):934-45.
2006: Anna Maria Wolf; Dominik Wolf; Matías A Avila; Alexander R Moschen; Carmen Berasain; Barbara Enrich; Holger Rumpold; Herbert Tilg
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice.
Journal of hepatology 2006;44(3):537-43.
2006: Matthias Lechner; Herbert Tilg; Josef Rieder
Analysis of volatile compounds emitted by the Helicobacter pylori reference strain NCTC 11637 in vitro.
Helicobacter 2006;11(1):66.
2005: Günther Neumayr; Othmar Ludwiczek; Helmut Hoertnagl; Rudolf Pfister; Guenther Mitterbauer; Alexander R Moschen; Daniela Novick; Menachem Rubinstein; Herbert Tilg
The impact of prolonged strenuous endurance exercise on interleukin 18 and interleukin 18 binding protein in recreational cyclists.
International journal of sports medicine 2005;26(10):836-40.
2005: Alexander R Moschen; Arthur Kaser; Sylvia Stadlmann; Gunda Millonig; Susanne Kaser; Petra Mühllechner; Andrzej Habior; Ivo W Graziadei; Wolfgang Vogel; Herbert Tilg
The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Journal of hepatology 2005;43(6):973-83.
2005: Julie R Jonsson; Alexander R Moschen; Ingrid J Hickman; Michelle M Richardson; Susanne Kaser; Andrew D Clouston; Elizabeth E Powell; Herbert Tilg
Adiponectin and its receptors in patients with chronic hepatitis C.
Journal of hepatology 2005;43(6):929-36.
2005: Matthias Lechner; Alban Karlseder; David Niederseer; Philipp Lirk; Andreas Neher; Josef Rieder; Herbert Tilg
H. pylori infection increases levels of exhaled nitrate.
Helicobacter 2005;10(5):385-90.
2005: Anna Maria Wolf; Dominik Wolf; Holger Rumpold; Susanne Ludwiczek; Barbara Enrich; Guenther Gastl; Günter Weiss; Herbert Tilg
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(38):13622-7.
2005: Susanne Kaser; Alexander R Moschen; Arthur Kaser; Othmar Ludwiczek; Christoph Ebenbichler; Wolfgang Vogel; Werner Jaschke; Josef R Patsch; Herbert Tilg
Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis.
Journal of internal medicine 2005;258(3):274-80.
2005: Herbert Tilg; Arthur Kaser
Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress?
Gut 2005;54(8):1057-9.
2005: Dominik Wolf; Kathrin Hochegger; Anna Maria Wolf; Holger F Rumpold; Guenther Gastl; Herbert Tilg; Gert Mayer; Eberhard Gunsilius; Alexander R Rosenkranz
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice.
Journal of the American Society of Nephrology : JASN 2005;16(5):1360-70.
2005: Herbert Tilg; Anna Maria Wolf
Adiponectin: a key fat-derived molecule regulating inflammation.
Expert opinion on therapeutic targets 2005;9(2):245-51.
2005: Alexander R Moschen; Arthur Kaser; Barbara Enrich; Othmar Ludwiczek; M Gabriel; P Obrist; A M Wolf; Herbert Tilg
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
Gut 2005;54(4):479-87.
2005: Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Herbert Tilg
Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease.
European cytokine network 2005;16(1):27-33.
2005: Susanne Kaser; Alexander R Moschen; A Cayon; Arthur Kaser; J Crespo; F Pons-Romero; Christoph Ebenbichler; Josef R Patsch; Herbert Tilg
Adiponectin and its receptors in non-alcoholic steatohepatitis.
Gut 2005;54(1):117-21.
2005: Nicole Kaneider; Arthur Kaser; Stefan Dunzendorfer; Herbert Tilg; Josef R Patsch; Christian Wiedermann
Neurokinin-1 receptor interacts with PrP(106-126)-induced dendritic cell migration and maturation.
Journal of neuroimmunology 2005;158(1-2):153-8.
2004: Othmar Ludwiczek; Edouard Vannier; Ingo Borggraefe; Arthur Kaser; B Siegmund; Charles A Dinarello; Herbert Tilg
Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
Clinical and experimental immunology 2004;138(2):323-9.
2004: Anna Maria Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.
Biochemical and biophysical research communications 2004;323(2):630-5.
2004: Clemens Molnar; Elena R Garcia-Trevijano; Othmar Ludwiczek; Dominique Talabot; Arthur Kaser; José M Mato; Gernot Fritsche; Günter Weiss; Cem Gabay; Matías A Avila; Herbert Tilg
Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist.
European cytokine network 2004;15(4):303-11.
2004: Anna Maria Wolf; Dominik Wolf; Holger Rumpold; Alexander R Moschen; Arthur Kaser; Peter Obrist; Dietmar Fuchs; Gerald Brandacher; Christiane Winkler; Karel Geboes; Paul Rutgeerts; Herbert Tilg
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.
Clinical immunology (Orlando, Fla.) 2004;113(1):47-55.
2004: Herbert Tilg; Arthur Kaser
Diet and relapsing ulcerative colitis: take off the meat?
Gut 2004;53(10):1399-401.
2004: Rajeshwar P Mookerjee; Herbert Tilg; Roger Williams; Rajiv Jalan
Infliximab and alcoholic hepatitis.
Hepatology (Baltimore, Md.) 2004;40(2):499-500; author reply 500-1.
2004: Arthur Kaser; Susanne Kaser; Nicole Kaneider; Barbara Enrich; Christian Wiedermann; Herbert Tilg
Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression.
Blood 2004;103(2):648-55.
2004: Arthur Kaser; Othmar Ludwiczek; Sandra Holzmann; Alexander R Moschen; Günter Weiss; Barbara Enrich; Ivo W Graziadei; Stefan Dunzendorfer; Christian Wiedermann; Elisabeth Mürzl; Eveline Grasl; Zerina Jasarevic; Nikolaus Romani; Felix Offner; Herbert Tilg
Increased expression of CCL20 in human inflammatory bowel disease.
Journal of clinical immunology 2004;24(1):74-85.
2003: Herbert Tilg; Harald Vogelsang; Othmar Ludwiczek; Herbert Lochs; Arthur Kaser; J-F Colombel; H Ulmer; Paul Rutgeerts; S Krüger; A Cortot; Geert D'Haens; Marieluise Harrer; Christoph Gasche; Fritz Wrba; I Kuhn; Walter Reinisch
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.
Gut 2003;52(12):1728-33.
2003: Susanne Kaser; Arthur Kaser; Anton Sandhofer; Christoph Ebenbichler; Herbert Tilg; Josef R Patsch
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.
Biochemical and biophysical research communications 2003;309(2):286-90.
2003: Nicole Kaneider; Arthur Kaser; Herbert Tilg; Giovanni Ricevuti; Christian Wiedermann
CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets.
International journal of immunopathology and pharmacology 2003;16(3):225-31.
2003: Nicole Kaneider; Arthur Kaser; Stefan Dunzendorfer; Herbert Tilg; Christian Wiedermann
Sphingosine kinase-dependent migration of immature dendritic cells in response to neurotoxic prion protein fragment.
Journal of virology 2003;77(9):5535-9.
2003: Herbert Tilg; Rajiv Jalan; Arthur Kaser; Nathan A Davies; Felix Offner; Stephen J Hodges; Othmar Ludwiczek; Debbie L Shawcross; Heinz Zoller; Akeel Alisa; Rajeshwar P Mookerjee; Ivo W Graziadei; Christian Datz; Michael Trauner; Detlef Schuppan; Peter Obrist; Wolfgang Vogel; Roger Williams
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.
Journal of hepatology 2003;38(4):419-25.
2003: Othmar Ludwiczek; Arthur Kaser; Herbert Tilg
Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases.
International journal of colorectal disease 2003;18(2):142-7.
2002: Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.
Journal of clinical immunology 2002;22(6):331-7.
2002: Herbert Tilg; Hannes Gaenzer
Splanchnic blood flow determination in patients with suspected chronic intestinal ischaemia.
European journal of gastroenterology & hepatology 2002;14(11):1169-71.
2002: Arthur Kaser; Othmar Ludwiczek; Peter Waldenberger; Werner Jaschke; Wolfgang Vogel; Herbert Tilg
Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting.
Liver 2002;22(5):380-7.
2002: Herbert Tilg; Arthur Kaser
Antitumour necrosis factor therapy in Crohn's disease.
Expert opinion on biological therapy 2002;2(7):715-21.
2002: Herbert Tilg; Hanno Ulmer; Arthur Kaser; Günter Weiss
Role of IL-10 for induction of anemia during inflammation.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(4):2204-9.
2002: Arthur Kaser; D Novick; M Rubinstein; B Siegmund; Barbara Enrich; Robert O Koch; Wolfgang Vogel; S H Kim; C A Dinarello; Herbert Tilg
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.
Clinical and experimental immunology 2002;129(2):332-8.
2002: Susanne Kaser; Arthur Kaser; Wolfgang Vogel; Josef R Patsch; Herbert Tilg
Interferon-alpha suppresses leptin levels: studies in interferon-alpha treated patients with hepatitis C virus infection and murine adipocytes.
European cytokine network 2002;13(2):225-9.
2002: Herbert Tilg; C van Montfrans; A van den Ende; Arthur Kaser; Sander J H van Deventer; S Schreiber; M Gregor; Othmar Ludwiczek; Paul Rutgeerts; Christoph Gasche; J C Koningsberger; L Abreu; I Kuhn; M Cohard; LeBeaut Pierre Alexandre; Paul C Grint; Günter Weiss
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.
Gut 2002;50(2):191-5.
2001: Arthur Kaser; Gerald Brandacher; W Steurer; Susanne Kaser; Felix Offner; Heinz Zoller; Igor Theurl; W Widder; Clemens Molnar; Othmar Ludwiczek; Michael B Atkins; J W Mier; Herbert Tilg
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.
Blood 2001;98(9):2720-5.
2001: Clemens Molnar; M Lechleitner; G Wetscher; Herbert Tilg
A woman with vomiting and depression.
Lancet 2001;358(9288):1154.
2001: Herbert Tilg
Cytokines and liver diseases.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2001;15(10):661-8.
2001: Othmar Ludwiczek; Arthur Kaser; Robert O Koch; Wolfgang Vogel; WW Cruikshank; Herbert Tilg
Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death.
European cytokine network 2001;12(3):478-86.
2001: Patrizia Stoitzner; Gudrun Ratzinger; Franz Koch; Katrin Janke; T Schöller; Arthur Kaser; Herbert Tilg; W W Cruikshank; Peter Fritsch; Nikolaus Romani
Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way.
The Journal of investigative dermatology 2001;116(5):641-9.
2001: Stefan Dunzendorfer; Arthur Kaser; Christian Meierhofer; Herbert Tilg; Christian Wiedermann
Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(4):2167-72.
2000: Herbert Tilg; A M Diehl
Cytokines in alcoholic and nonalcoholic steatohepatitis.
The New England journal of medicine 2000;343(20):1467-76.
2000: Arthur Kaser; Stefan Dunzendorfer; Felix Offner; Othmar Ludwiczek; Barbara Enrich; Robert O Koch; WW Cruikshank; Christian Wiedermann; Herbert Tilg
B lymphocyte-derived IL-16 attracts dendritic cells and Th cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(5):2474-80.
2000: Stefan Dunzendorfer; Arthur Kaser; Christian Meierhofer; Herbert Tilg; Christian Wiedermann
Dendritic cell migration in different micropore filter assays.
Immunology letters 2000;71(1):5-11.
1999: Arthur Kaser; Barbara Enrich; Othmar Ludwiczek; Wolfgang Vogel; Herbert Tilg
Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.
Clinical and experimental immunology 1999;118(1):71-7.
1999: Arthur Kaser; S Nagata; Herbert Tilg
Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression.
Cytokine 1999;11(10):736-43.
1999: Arthur Kaser; Stefan Dunzendorfer; Felix Offner; T Ryan; A Schwabegger; WW Cruikshank; Christian Wiedermann; Herbert Tilg
A role for IL-16 in the cross-talk between dendritic cells and T cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(6):3232-8.
1999: Arthur Kaser; W Vogel; Herbert Tilg
Plasma levels of soluble Fas during treatment of chronic hepatitis C patients with interferon alpha.
Journal of hepatology 1999;31(3):575.
1999: Arthur Kaser; Florian Deisenhammer; T Berger; Herbert Tilg
Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.
Lancet 1999;353(9162):1413-4.
1999: Edouard Vannier; Arthur Kaser; Michael B Atkins; Giamila Fantuzzi; Charles A Dinarello; J W Mier; Herbert Tilg
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
European cytokine network 1999;10(1):37-42.
1998: Herbert Tilg; Arthur Kaser
IL-6 and arthritis: a detrimental or beneficial mediator?
IDrugs : the investigational drugs journal 1998;1(8):890-5.
1998: Arthur Kaser; Clemens Molnar; Herbert Tilg
Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha.
Cytokine 1998;10(2):75-81.
1997: Herbert Tilg
New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.
Gastroenterology 1997;112(3):1017-21.
1997: Hubert Schwaighofer; G Oberhuber; H Hebart; Hermann Einsele; Manfred Herold; David Nachbaur; Brigitte Eibl; Herbert Tilg; Gabriele Kropshofer; James L M Ferrara; Dietger Niederwieser
Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
Transplantation 1997;63(1):52-6.
1996: R Geiger; Helmut Ellemunter; Franz-Martin Fink; M Falk; Herbert Tilg
Circulating interleukin-1 receptor antagonist levels in neonates.
European journal of pediatrics 1996;155(9):811-4.
1996: M J Aman; T Tretter; I Eisenbeis; G Bug; T Decker; Walter Aulitzky; Herbert Tilg; Christoph Huber; Christian Peschel
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes.
Blood 1996;87(11):4731-6.
1996: David Nachbaur; Dietger Niederwieser; G Aichinger; Walter Aulitzky; Herbert Tilg; Brigitte Eibl; P König; C Gattringer; O Majdic; Hannes Stockinger; Raimund Margreiter; G Oberhuber; A M Födinger; Hubert Schwaighofer; Christoph Huber
CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo.
Immunobiology 1996;195(1):33-46.
1995: Herbert Tilg; M B Atkins; C A Dinarello; J W Mier
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.
Cytokine 1995;7(7):734-9.
1995: A Wilmer; B Nölchen; Herbert Tilg; M Herold; Christoph Pechlaner; G Judmaier; Otto Dietze; Wolfgang Vogel
Serum neopterin concentrations in chronic liver disease.
Gut 1995;37(1):108-12.
1995: Herbert Tilg; W Vogel; C A Dinarello
Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans.
Blood 1995;85(2):433-5.
1994: F Hladik; J A Tratkiewicz; Herbert Tilg; W Vogel; U Schwulera; M Krönke; Walter Aulitzky; Christoph Huber
Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(4):1449-54.
1994: Herbert Tilg; L Shapiro; E Vannier; D D Poutsiaka; E Trehu; Michael B Atkins; Charles A Dinarello; James W Mier
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(6):3189-98.
1994: Herbert Tilg; E Trehu; L Shapiro; D Pape; Michael B Atkins; Charles A Dinarello; James W Mier
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.
Cytokine 1994;6(2):215-9.
1994: Herbert Tilg; E Trehu; Michael B Atkins; Charles A Dinarello; James W Mier
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.
Blood 1994;83(1):113-8.
1993: Herbert Tilg; W Vogel; Christian Wiedermann; L Shapiro; M Herold; G Judmaier; Charles A Dinarello
Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.
Hepatology (Baltimore, Md.) 1993;18(5):1132-8.
1993: Walter Aulitzky; Christian Peschel; D Desprès; J Aman; P Trautman; Herbert Tilg; G Rudolf; H Hüttmann; J Obermeier; M Herold
Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
Annals of hematology 1993;67(5):205-11.
1993: Herbert Tilg; E Vannier; G Vachino; Charles A Dinarello; James W Mier
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells.
The Journal of experimental medicine 1993;178(5):1629-36.
1993: Herbert Tilg; Wolfgang Vogel; J Tratkiewicz; Walter Aulitzky; M Herold; M Gruber; D Geissler; F Umlauft; G Judmaier; U Schwulera
Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Journal of hepatology 1993;19(2):259-67.
1993: Herbert Tilg; D Pape; E Trehu; L Shapiro; Michael B Atkins; Charles A Dinarello; James W Mier
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.
Journal of immunological methods 1993;163(2):253-8.
1993: Herbert Tilg; Brigitte Eibl; M Pichl; Anne Gächter; M Herold; J Brankova; Christoph Huber; Dietger Niederwieser
Immune response modulation by pentoxifylline in vitro.
Transplantation 1993;56(1):196-201.
1993: Herbert Tilg; James W Mier; W Vogel; Walter Aulitzky; Christian Wiedermann; E Vannier; C Huber; Charles A Dinarello
Induction of circulating IL-1 receptor antagonist by IFN treatment.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(10):4687-92.
1992: Michael B Atkins; G Vachino; Herbert Tilg; D D Karp; N J Robert; K Kappler; James W Mier
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1802-9.
1992: Peter Lechleitner; N Genser; Johannes Mair; J Maier; M Herold; H Beimpold; B Föger; F Dienstl; Bernd Puschendorf; Herbert Tilg
Pentoxifylline influences acute-phase response in acute myocardial infarction.
The Clinical investigator 1992;70(9):755.
1992: Herbert Tilg; A Wilmer; Wolfgang Vogel; M Herold; B Nölchen; G Judmaier; C Huber
Serum levels of cytokines in chronic liver diseases.
Gastroenterology 1992;103(1):264-74.
1992: Herbert Tilg; J Nordberg; W Vogel; T A Luger; M Herold; Walter Aulitzky; Raimund Margreiter; Christoph Huber
Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation.
Transplantation 1992;54(1):142-6.
1992: A Wilmer; Herbert Tilg; Wolfgang Vogel
[Does the determination of serum neopterin secure blood transfusion?].
Deutsche medizinische Wochenschrift (1946) 1992;117(19):765.
1992: Herbert Tilg; Alfred Königsrainer; R Krausler; Walter Aulitzky; Raimund Margreiter; G Reibnegger; H Wachter; Christoph Huber
Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantation.
Transplantation 1992;53(4):804-8.
1992: Herbert Tilg; M Ceska; Wolfgang Vogel; M Herold; Raimund Margreiter; Christoph Huber
Interleukin-8 serum concentrations after liver transplantation.
Transplantation 1992;53(4):800-3.
1992: Herbert Tilg; U Westhoff; W Vogel; Walter Aulitzky; M Herold; R Margreiter; C Huber; H Grosse-Wilde
Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplantation.
Journal of hepatology 1992;14(2-3):417-9.
1991: Christian Wiedermann; Franz J. Wiedermann; M Herold; Herbert Tilg; Nicolas Moes; V Mühlberger; H Beimpold; E Knapp
Plasma levels of atrial natriuretic peptide and tumor necrosis factor-alpha during transient myocardial ischemia in patients with stable angina.
Klinische Wochenschrift 1991;69(20):944.
1991: Walter E Aulitzky; Hans Grosse-Wilde; U Westhoff; Herbert Tilg; W Aulitzky; Guenther Gastl; M Herold; Christoph Huber
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).
Clinical and experimental immunology 1991;86(2):236-9.
1991: Christian Wiedermann; Wolfgang Vogel; Herbert Tilg; Franz J. Wiedermann; M Herold; U Zilian; T Wohlfarter; M Gruber; H Braunsteiner
Suppression of thyroid function by interferon-alpha 2 in man.
Naunyn-Schmiedeberg's archives of pharmacology 1991;343(6):665-8.
1991: Walter E Aulitzky; Herbert Tilg; W Vogel; W Aulitzky; M Berger; Guenther Gastl; M Herold; Christoph Huber
Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.
Annals of hematology 1991;62(1):25-31.
1991: Walter Aulitzky; Herbert Tilg; Guenther Gastl; R Mull; R Flener; W Vogel; M Herold; M Berger; G Judmaier; Christoph Huber
Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.
European journal of cancer (Oxford, England : 1990) 1991;27(4):462-7.
1990: Dietger Niederwieser; M Herold; W Woloszczuk; Walter Aulitzky; B Meister; Herbert Tilg; Guenther Gastl; R Bowden; Christoph Huber
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.
Transplantation 1990;50(4):620-5.
1990: Wolfgang Vogel; Herbert Tilg; M Herold; Otto Dietze; Walter Aulitzky; Raimund Margreiter; Christoph Huber
Cytokine production after liver transplantation.
Transplantation proceedings 1990;22(4):1854.
1990: Herbert Tilg; Wolfgang Vogel; Walter Aulitzky; M Herold; Alfred Königsrainer; Raimund Margreiter; Christoph Huber
Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation.
Transplantation 1990;49(6):1074-80.
1990: D Geissler; Guenther Gastl; Walter Aulitzky; Herbert Tilg; S Gaggl; Günther Konwalinka; Christoph Huber
Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Leukemia research 1990;14(7):629-36.
1989: Herbert Tilg; Wolfgang Vogel; Walter Aulitzky; Diether Schönitzer; Raimund Margreiter; Otto Dietze; G Judmaier; H Wachter; Christoph Huber
Neopterin excretion after liver transplantation and its value in differential diagnosis of complications.
Transplantation 1989;48(4):594-9.
1989: Guenther Gastl; M Werter; B De Pauw; C Nerl; Walter Aulitzky; I von Lüttichau; Herbert Tilg; Josef Thaler; A Lang; K Abbrederis
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
Leukemia 1989;3(6):453-60.
1988: J Troppmair; K Nachbaur; M Herold; Walter Aulitzky; Herbert Tilg; Guenther Gastl; P Bieling; B Kotlan; R Flener; B Mull
In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS).
Clinical and experimental immunology 1988;74(3):392-7.
1988: Walter Aulitzky; Herbert Tilg; M Herold; M Berger; Wolfgang Vogel; G Judmaier; Guenther Gastl; B Mull; R Flener; J Wiegele
Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
Journal of interferon research 1988;8(5):655-64.
1988: Walter Aulitzky; Herbert Tilg; Dietger Niederwieser; Georg Riccabona; L Obendorf; Raimund Margreiter; Walter Pfaller; Christoph Huber
Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients.
Clinical nephrology 1988;29(5):248-52.
1987: D Schönitzer; Herbert Tilg; Dietger Niederwieser; Walter Aulitzky; Raimund Margreiter; Christoph Huber
ABO-incompatible renal transplantation: report of two transplants from AB donors to A recipients.
Transplantation proceedings 1987;19(6):4547-8.
1987: Christoph Huber; Walter Aulitzky; Herbert Tilg; I von Lüttichau; J Troppmair; K Nachbauer; Guenther Gastl
Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Leukemia 1987;1(4):355-7.
1986: Guenther Gastl; Walter Aulitzky; Herbert Tilg; K Nachbaur; J Troppmair; R Flener; Christoph Huber
A biological approach to optimize interferon treatment in hairy cell leukemia.
Immunobiology 1986;172(3-5):262-8.
1986: Walter Aulitzky; Guenther Gastl; Herbert Tilg; J Troppmair; E Leiter; D Geissler; R Flener; Christoph Huber
[Interferon-alpha in the treatment of hematologic neoplasms].
Wiener medizinische Wochenschrift (1946) 1986;136(7-8):172-81.
1985: Walter Aulitzky; Guenther Gastl; J Troppmair; Herbert Tilg; K Abbrederis; C Nerl; R Flener; Hartmut Rokos; C Huber
[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
Acta medica Austriaca 1985;12(5):115-21.